Alzheimer’s & Dementia Care
-
FDA Approves Auvelity, a First-in-Class Non-Antipsychotic Treatment for Agitation in Alzheimer’s Disease
The U.S. Food and Drug Administration (FDA) has granted approval for Auvelity (dextromethorphan-bupropion) as a novel, first-in-class treatment specifically for…
Read More » -
June: A Pivotal Month for Alzheimer’s and Brain Awareness, Catalyzing Research and Action Against a Global Health Challenge
June marks a critical period for global public health as the Alzheimer’s Association spearheads Alzheimer’s & Brain Awareness Month, a…
Read More » -
Zunveyl (benzgalantamine) Associated with Provider-Reported Improvements in Alzheimer’s Patients in Real-World Study
Top-line data from the BEACON study, a real-world observational study, indicate that Zunveyl (benzgalantamine) was associated with provider-reported improvements across…
Read More » -
Real-World BEACON Study Highlights Zunveyl’s Positive Impact on Alzheimer’s Patients in Long-Term Care, Paving Way for Further Research
Top-line data from the BEACON study, a significant real-world investigation, suggest that Zunveyl (benzgalantamine) was associated with notable improvements across…
Read More » -
June Marks Critical Period for Alzheimer’s and Brain Awareness, Highlighting Urgent Need for Research and Action
June has once again been designated as Alzheimer’s & Brain Awareness Month (ABAM), a crucial period orchestrated by the Alzheimer’s…
Read More » -
FDA Reviews Expanded Approval for Subcutaneous Leqembi Iqlik, Offering At-Home Treatment from Initiation
The U.S. Food and Drug Administration (FDA) is currently reviewing a supplemental Biologics License Application (sBLA) submitted by Biogen and…
Read More » -
Researchers Advocate for Expanded Studies into Lymphovenous Anastomosis as a Novel Therapeutic Strategy for Alzheimer’s Disease
A compelling call for expanded research into lymphovenous anastomosis (LVA), a surgical procedure designed to enhance the clearance of molecular…
Read More » -
Anavex Life Sciences Reports Sustained Long-Term Benefits of Oral Blarcamesine in Early Alzheimer’s Disease Over Nearly Three Years
Copenhagen, Denmark – Anavex Life Sciences, a biopharmaceutical company focused on central nervous system disorders, has announced that the therapeutic…
Read More » -
FDA Approves Auvelity, a First-in-Class Non-Antipsychotic Treatment for Agitation in Alzheimer’s Disease
The U.S. Food and Drug Administration (FDA) has granted approval to Auvelity (dextromethorphan-bupropion), marking a significant advancement in the management…
Read More » -
Alzheimer’s & Brain Awareness Month Mobilizes Global Efforts to Combat Rising Dementia Crisis and Advance Research
June marks Alzheimer’s & Brain Awareness Month, a pivotal period when the Alzheimer’s Association spearheads a comprehensive array of initiatives…
Read More »
